
    
      All patients who fulfill the eligibility criteria for this trial , will initiate at least one
      treatment course of ofatumumab, and depending of subsequent worsening in disease activity
      will be eligible to received further treatment through the 156 week treatment period: a
      maximum of a further 8 treatment courses will be given at individualized time intervals . The
      interval between each treatment course will be at least 16 weeks with the last treatment
      course given no later than week 130 after baseline (Visit 2A).

      After each treatment course the patients will attend their next trial visit 8 weeks after
      Infusion 1, followed by trial visits every 4 weeks up to Week 24, and subsequently every 8
      weeks until the next treatment course.

      After completing the Treatment Period or after withdrawing from the Treatment Period
      prematurely patients will be followed every 12 weeks (Follow-up Period) until CD19+ cells
      &/or IgG levels have returned to baseline or normal levels.
    
  